Thread by @sammodacharya

Clearly the conclusion is biased because there is no significant reduction in mortality showing it is ineffective in serious cases who actually need treatment. As a clinical #Pharmacologist my conclusion is: #Remdesivir should not be standard of care for any patient of #COVID19

https://twitter.com/NBCNews/status/1255541788154224641

The mortality rate as stated reduced from 11% to 8% (3%) that they admit insignificant despite being "highly powered multicenter randomised controlled trial (RCT)".This is the clue to understand that they are trying to make this expensive drug as standard of care. #Remdesivir

The preoccupation to prove efficacy of so called modern synthetic drugs with patents is so heavy for obvious reasons that it is almost impossible to "prove" the efficacy of traditionally used antiviral formulations or herbs despite having so much in vitro as well as vivo evidence

There are innumerable research articles published in international journals on specific and non specific #antiviral or immune enhancing effects of our herbs.E.g: Gycyrrhizin in.#Glycyrrhiza glabra (#Yashtimadhu) against SARS-1 #Coronavirus #TheLancet
pubmed.ncbi.nlm.nih.gov/12814717/

Binding angiotensin-converting enzyme II (ACE2), downregulating proinflammatory cytokines, inhibiting accumulation of intracellular reactive oxygen species (ROS), inhibiting thrombin, inhibiting the hyperproduction of airway exudates& inducing endogenous interferon.
#Glycyrrhizin

"Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19."
europepmc.org/article/pmc/pm…